
    
      All subjects will be receive QD doses of HEC74647 or the matching placebo for 3 days to
      assess the the tolerability, pharmacokinetics and antiviral activity at specified time-points
      during the study.All subjects also will be monitored for up to 8 days post-dose to determine
      the persistence of viral mutations.
    
  